No in-house lobbyists. The figure is what 5 outside firms reported being paid by the company (LD-2, rounded to $10K). This PAC gives money raised from the company’s employees; the company itself can’t give to campaigns from its treasury.
Spend by quarter Pro
Free account See ProWhat they lobby on
MethodAlexion Pharmaceuticals reported federal lobbying in 8 of the last 8 quarters (Q4 2024 to Q3 2026), through 5 outside firms. What follows is what the filings say it lobbied on, not which way.
Issue areas ranked by quarters filedQ4 24 → Q3 26
- Health Issues8/8
- Medicare/Medicaid8/8
Bills named in the filings 8 bills, this period
- H.R. 946 ORPHAN Cures Act6 filings
- H.R. 1672 Maintaining Investments in New Innovation Act2 filings
- S. 3131 / H.R. 5539, 118th ORPHAN Cures Act2 filings
- S. 864 HELP Copays Act2 filings
- H.R. 5539 POW Priority Care Act of 20251 filing
3 more, 4 named in only one filing · Show all 8
From the filings
“Issues related to rare disease pharmaceuticals, Orphan Cures H.R. 946, and Pediatric Priority Review Voucher.”
“General issues related to the rare disease pharmaceutical ecosystem.”
Contacted as listed on the filings
- U.S. House
- U.S. Senate
- CMS
- HHS
- White House Office
The House and Senate appear in every quarter; agencies in 3 of 8.
Every filing since 2015 Pro
Free account See ProSource: Lobbying Disclosure Act filings (LD-2) by Alexion Pharmaceuticals, Senate Office of Public Records. Filings are due 20 days after each quarter ends.
From FEC filings: direct gifts this PAC reported, net of refunds · How we count
Gave directly to 43 sitting members of Congress and 1 other candidate in 2025–26.
See every candidate and member Alexion Pharmaceuticals gave to directly, how much, and how its money splits between the parties.
This part is in Pro. A free account lets you follow up to 3 people and get a weekly email about them; upgrade whenever you need more.
Create a free account See what Pro adds Log in